STOCK TITAN

Oramed agrees to pay $125K in legal fees and expenses

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Oramed Pharmaceuticals Inc. amended its bylaws on June 28, 2026, mooting the stockholder action brought by purported stockholder Agnes Lotz. The Delaware Court of Chancery dismissed the action on July 2, 2026, retaining jurisdiction solely to resolve any application by Lotz’s counsel for attorneys’ fees and expenses. Oramed agreed to pay $125,000 in attorneys’ fees and expenses in connection with the mooted claims, without admitting fault or wrongdoing.

Filing Explained

The dispute concerned Article III, Section 11 of Oramed’s bylaws, which governs stockholder action by written consent; the complaint alleged violations of DGCL Sections 213(b) and 228(a), which Oramed denied.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Attorneys’ fees and expenses $125,000 Amount Oramed agreed to pay plaintiff’s counsel in connection with the mooted claims
mooted regulatory
"Action was mooted on June 28, 2026"
retaining jurisdiction regulatory
"while retaining jurisdiction solely to resolve any application"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did ORMP agree to pay plaintiff’s counsel?

Oramed agreed to pay $125,000 in attorneys’ fees and expenses to plaintiff’s counsel in connection with the mooted claims, without admitting fault or wrongdoing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001176309 0001176309 2026-11-05 2026-11-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): November 5, 2026

 

ORAMED PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

 

delaware   001-35813   98-0376008
(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

1185 Avenue of the Americas, Third Floor,
New York, New York
  10036
(Address of Principal Executive Offices)   (Zip Code)

 

844-967-2633

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol   Name of each exchange on which registered
Common Stock, par value $0.012   ORMP   The Nasdaq Capital Market,
Tel Aviv Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 8.01. Other Events.

 

On February 20, 2026, a purported stockholder of Oramed Pharmaceuticals Inc. (the “Company”) filed a putative class action in the Court of Chancery of the State of Delaware captioned Agnes Lotz v. Oramed Pharmaceuticals Inc., C.A. No. 2026-0244-PAF (Del. Ch.) (the “Action”). The Action challenged provisions of Article III, Section 11 of the Company’s bylaws governing stockholder action by written consent, alleging that they violated Sections 213(b) and 228(a) of the Delaware General Corporation Law (“DGCL”).

 

The Company denies that the challenged provisions of its bylaws violated the DGCL. However, the Company agreed to amend its bylaws to avoid the distraction and cost of needless litigation. The Action was mooted on June 28, 2026, when the Company amended its bylaws.

 

On July 2, 2026, the Court entered an order dismissing the Action while retaining jurisdiction solely to resolve any application by plaintiff’s counsel for attorneys’ fees and expenses. Without admitting fault or wrongdoing, the Company agreed to pay plaintiff’s counsel $125,000 in attorneys’ fees and expenses in connection with the mooted claims.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

November 19, 2026 ORAMED PHARMACEUTICALS INC.
 
  By: /s/ Nadav Kidron
  Name: Nadav Kidron
    President and CEO

 

 

2

 

Filing Exhibits & Attachments

3 documents

Keep reading